Drug intelligence / Profile preview

PTx325

Development stage: Unknown
Lead developer: Primal Therapies
Modality: Small Molecules

Overview

**PTx325** is a Primal Therapies small-molecule combination program for modulation of the oral microbiome. Publicly available material describes PTx325 as the animal-grade version of the same composition as human-grade PTx800. It is intended to selectively influence microbial metabolism in oral biofilms and microbiomes, supporting beneficial microbial communities while suppressing pathogenic microbial growth and activity. The individual active ingredients, molecular targets, formulation, route, and specific veterinary indication have not been publicly disclosed.

Targets

USP30 (Ubiquitin-specific peptidase 30)

Beyond the preview

Go deeper on PTx325.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTx325.

Explore the full profile